(Q36439704)

14 August 2017

1 reference

title

Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences? (English)

1 reference

14 August 2017

0 references

1

1 reference

14 August 2017

Gerd Geisslinger

2

1 reference

PubMed ID

16586083

14 August 2017

language of work or name

1 reference

4 April 2006

1 reference

14 August 2017

17

1 reference

Naunyn-Schmiedeberg's Archives of Pharmacology

inferred from page(s)

published in

1 reference

14 August 2017

373

1 reference

14 August 2017

1

1 reference

14 August 2017

1-17

1 reference

https://scigraph.springernature.com/pub.10.1007/s00210-006-0044-7

14 August 2017

0 references

cites work

AZD3582 increases heme oxygenase-1 expression and antioxidant activity in vascular endothelial and gastric mucosal cells

1 reference

https://api.crossref.org/works/10.1007%2FS00210-006-0044-7

Prediction of heart failure by amino terminal-pro-B-type natriuretic peptide and C-reactive protein in subjects with cerebrovascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-006-0044-7

Roles of cyclooxygenase (COX)-1 and COX-2 in prostanoid production by human endothelial cells: selective up-regulation of prostacyclin synthesis by COX-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-006-0044-7

Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-006-0044-7

Role of macula densa cyclooxygenase-2 in renovascular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-006-0044-7

Heme oxygenase-1 inhibits atherosclerotic lesion formation in ldl-receptor knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-006-0044-7

Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-006-0044-7

Inhibition of vascular smooth muscle cell proliferation by sodium salicylate mediated by upregulation of p21(Waf1) and p27(Kip1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-006-0044-7

Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-006-0044-7

Induction of cyclooxygenase-2 and activation of nuclear factor-kappaB in myocardium of patients with congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-006-0044-7

Hypoxia induces myocyte-dependent COX-2 regulation in endothelial cells: role of VEGF

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-006-0044-7

Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-006-0044-7

NSAIDs and blood pressure. Clinical importance for older patients

21 January 2018

1 reference

12 December 2020

Heme oxygenase-1 induction may explain the antioxidant profile of aspirin

1 reference

12 December 2020

A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke

1 reference

12 December 2020

Colocalization of prostacyclin synthase with prostaglandin H synthase-1 (PGHS-1) but not phorbol ester-induced PGHS-2 in cultured endothelial cells.

1 reference

12 December 2020

Cyclooxygenase isozyme expression and intimal hyperplasia in a rat model of balloon angioplasty

1 reference

12 December 2020

N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes

1 reference

12 December 2020

N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease

1 reference

12 December 2020

COX-2 selective non-steroidal anti-inflammatory drugs and cardiovascular disease.

1 reference

12 December 2020

Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs

1 reference

12 December 2020

Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: a randomized placebo-controlled study

1 reference

12 December 2020

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

1 reference

12 December 2020

Need for common internal controls when assessing the relative efficacy of pharmacologic agents using a meta-analytic approach: case study of cyclooxygenase 2-selective inhibitors for the treatment of osteoarthritis

1 reference

12 December 2020

Celecoxib, a cyclooxygenase-2 inhibitor, reduces neointimal hyperplasia through inhibition of Akt signaling

1 reference

12 December 2020

Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles

1 reference

12 December 2020

Comparison of inhibitory effects of meloxicam and diclofenac on human thromboxane biosynthesis after single doses and at steady state

1 reference

12 December 2020

Prediction of myocardial infarction by N-terminal-pro-B-type natriuretic peptide, C-reactive protein, and renin in subjects with cerebrovascular disease.

1 reference

12 December 2020

Cardiovascular protection and blood pressure reduction: a meta-analysis

1 reference

12 December 2020

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial

1 reference

12 December 2020

N-terminal brain natriuretic peptide is a more powerful predictor of mortality than endothelin-1, adrenomedullin and tumour necrosis factor-alpha in patients referred for consideration of cardiac transplantation.

1 reference

12 December 2020

Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2

1 reference

12 December 2020

Efficacy and safety of intravenous parecoxib sodium in relieving acute postoperative pain following gynecologic laparotomy surgery

1 reference

12 December 2020

Use of nonsteroidal anti-inflammatory drugs and the risk of first-time acute myocardial infarction

1 reference

12 December 2020

Cyclooxygenases, the kidney, and hypertension

1 reference

12 December 2020

Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors

1 reference

12 December 2020

Effects of COX-2 inhibitors on aortic prostacyclin production in cholesterol-fed rabbits

1 reference

12 December 2020

Loss of heterozygosity and microsatellite instability in human atherosclerotic plaques

1 reference

12 December 2020

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

1 reference

12 December 2020

Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery

1 reference

12 December 2020

Gene therapy strategy for long-term myocardial protection using adeno-associated virus-mediated delivery of heme oxygenase gene

1 reference

12 December 2020

Endothelial cell activation in patients with decompensated heart failure

1 reference

12 December 2020

A comparison of the effects of nabumetone vs meloxicam on serum thromboxane B2 and platelet function in healthy volunteers

1 reference

12 December 2020

Sulindac inhibits neointimal formation after arterial injury in wild-type and apolipoprotein E-deficient mice.

1 reference

12 December 2020

Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis

1 reference

12 December 2020

A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure

1 reference

12 December 2020

COX-2 and beyond: Approaches to prostaglandin inhibition in human disease

1 reference

12 December 2020

Endothelial cell confluence regulates cyclooxygenase-2 and prostaglandin E2 production that modulate motility.

1 reference

12 December 2020

Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2.

1 reference

12 December 2020

Cyclo-oxygenase-2 inhibition increases blood pressure in rats.

1 reference

12 December 2020

Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers

1 reference

12 December 2020

Nonsteroidal anti-inflammatory drug use and acute myocardial infarction

1 reference

12 December 2020

COX-2–Dependent Cardiac Failure in Gh/tTG Transgenic Mice

1 reference

12 December 2020

Blood pressure and the risk of cardiovascular disease

1 reference

12 December 2020

Lipid mediator class switching during acute inflammation: signals in resolution.

1 reference

12 December 2020

15-epi-lipoxin A4-mediated induction of nitric oxide explains how aspirin inhibits acute inflammation

1 reference

12 December 2020

A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group

1 reference

12 December 2020

Risk of cardiovascular events and rofecoxib: cumulative meta-analysis

1 reference

12 December 2020

Microsatellite Instability in Human Atherosclerotic Plaques

1 reference

12 December 2020

Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis

1 reference

12 December 2020

Use of ramipril in preventing stroke: double blind randomised trial

1 reference

12 December 2020

Congestive heart failure due to nonsteroidal anti-inflammatory drugs in the elderly

1 reference

12 December 2020

Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension

1 reference

12 December 2020

Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice

1 reference

12 December 2020

Indobufen in the prevention of thromboembolic complications in patients with heart disease. A randomized, placebo-controlled, double-blind study

1 reference

12 December 2020

Celecoxib, a selective cyclooxygenase-2 inhibitor, decreases monocyte chemoattractant protein-1 expression and neointimal hyperplasia in the rabbit atherosclerotic balloon injury model

1 reference

12 December 2020

Promoter analysis of the gene encoding the beta-subunit of the rat amiloride-sensitive epithelial sodium channel

1 reference

12 December 2020

Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study

1 reference

12 December 2020

A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273].

1 reference

12 December 2020

Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear str

1 reference

12 December 2020

Cyclooxygenase-2--specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients

1 reference

12 December 2020

Cyclooxygenase-2 inhibition attenuates lipopolysaccharide-induced cardiovascular failure.

1 reference

12 December 2020

Blood pressure in Native Americans switched from celecoxib to rofecoxib

1 reference

12 December 2020

Cyclooxygenase-independent actions of cyclooxygenase inhibitors

1 reference

12 December 2020

Oral valdecoxib and injected parecoxib for acute postoperative pain: a quantitative systematic review

1 reference

12 December 2020

Cyclooxygenase-2 inhibitor treatment improves left ventricular function and mortality in a murine model of doxorubicin-induced heart failure

1 reference

12 December 2020

Cyclooxygenase-2-dependent prostacyclin formation is regulated by low density lipoprotein cholesterol in vitro

1 reference

12 December 2020

Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis

1 reference

12 December 2020

A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group

1 reference

12 December 2020

Novel lipid mediator regulators of endothelial cell proliferation and migration: aspirin-triggered-15R-lipoxin A(4) and lipoxin A(4).

1 reference

12 December 2020

Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without ST-segment elevation: the Nonsteroidal Anti-Inflammatory Drugs in Unstable Angina Treatment-2 (NUT-2) pilot study

1 reference

12 December 2020

Adenylate cyclase-coupled vasopressin receptor activates AQP2 promoter via a dual effect on CRE and AP1 elements

1 reference

12 December 2020

Effect of rofecoxib therapy on measures of health-related quality of life in patients with osteoarthritis

1 reference

12 December 2020

Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults

1 reference

12 December 2020

N-terminal pro-brain natriuretic peptide on admission has prognostic value across the whole spectrum of acute coronary syndromes

1 reference

12 December 2020

Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using Prescription-Event Monitoring (PEM) data

1 reference

12 December 2020

Genomic instability in the type II TGF-beta1 receptor gene in atherosclerotic and restenotic vascular cells

1 reference

12 December 2020

Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports

1 reference

12 December 2020

Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism.

1 reference

12 December 2020

The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group

1 reference

12 December 2020

An observational, retrospective, cohort study of dosing patterns for rofecoxib and celecoxib in the treatment of arthritis

1 reference

12 December 2020

Plasma cystatin-C and development of coronary heart disease: The PRIME Study

1 reference

12 December 2020

COX-2-specific inhibitors: prescribing patterns in a large managed care health system and strategies to minimize costs.

1 reference

12 December 2020

Selective cyclo-oxygenase-2 inhibition with parecoxib acutely impairs endothelium-dependent vasodilatation in patients with essential hypertension

1 reference

12 December 2020

Coronary Vasoconstrictor Effect of Indomethacin in Patients with Coronary-Artery Disease

1 reference

12 December 2020

Intrathecally applied flurbiprofen produces an endocannabinoid-dependent antinociception in the rat formalin test

1 reference

12 December 2020

Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care.

1 reference

12 December 2020

Circulating endothelial progenitor cells and cardiovascular outcomes

1 reference

12 December 2020

Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study

1 reference

12 December 2020

Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protoco

1 reference

12 December 2020

Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis

1 reference

12 December 2020

Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial

1 reference

12 December 2020

Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population

1 reference

12 December 2020

Anandamide metabolism by fatty acid amide hydrolase in intact C6 glioma cells. Increased sensitivity to inhibition by ibuprofen and flurbiprofen upon reduction of extra- but not intracellular pH.

1 reference

12 December 2020

COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease

1 reference

12 December 2020

Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects

1 reference

12 December 2020

Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction

1 reference

12 December 2020

Association between naproxen use and protection against acute myocardial infarction

1 reference

12 December 2020

Cyclooxygenase inhibition restores nitric oxide activity in essential hypertension

1 reference

12 December 2020

Celecoxib induces heme-oxygenase expression in glomerular mesangial cells

1 reference

12 December 2020

Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs: a 6-week and a 1-year trial in patients with osteoarthritis. Osteoarthritis Studies Group

1 reference

12 December 2020

Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial

1 reference

12 December 2020

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

1 reference

12 December 2020

Absence of heme oxygenase-1 exacerbates myocardial ischemia/reperfusion injury in diabetic mice

1 reference

12 December 2020

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

1 reference

12 December 2020

A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents

1 reference

12 December 2020

NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics.

1 reference

12 December 2020

Selective COX-2 inhibition improves endothelial function in coronary artery disease

1 reference

12 December 2020

Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects

1 reference

12 December 2020

High glucose causes upregulation of cyclooxygenase-2 and alters prostanoid profile in human endothelial cells: role of protein kinase C and reactive oxygen species

1 reference

12 December 2020

Probucol protects against smooth muscle cell proliferation by upregulating heme oxygenase-1.

1 reference

12 December 2020

Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet

1 reference

12 December 2020

Overexpression of heme oxygenase-1 protects smooth muscle cells against oxidative injury and inhibits cell proliferation.

1 reference

12 December 2020

COX-2 inhibitors selectively block prostacyclin synthesis in endotoxin-exposed vascular smooth muscle cells

1 reference

12 December 2020

DNA damage as a new emerging risk factor in atherosclerosis.

1 reference

12 December 2020

Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension

1 reference

12 December 2020

Celecoxib decreases endothelial tissue factor expression through inhibition of c-Jun terminal NH2 kinase phosphorylation

1 reference

12 December 2020

N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults

1 reference

12 December 2020

Lipoxins: revelations on resolution

1 reference

12 December 2020

Blood pressure destabilization and related healthcare utilization among hypertensive patients using nonspecific NSAIDs and COX-2-specific inhibitors

1 reference

12 December 2020

Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis

1 reference

12 December 2020

Relationship between COX-2 specific inhibitors and hypertension

1 reference

12 December 2020

The Risk of Gastrointestinal Bleed, Myocardial Infarction, and Newly Diagnosed Hypertension in Users of Meloxicam, Diclofenac, Naproxen, and Piroxicam

1 reference

12 December 2020

Novel lipid mediator aspirin-triggered lipoxin A4 induces heme oxygenase-1 in endothelial cells

1 reference

12 December 2020

Genomic rearrangements on VCAM1, SELE, APEG1and AIF1 loci in atherosclerosis

1 reference

12 December 2020

Risk of cardiovascular events associated with selective COX-2 inhibitors

1 reference

12 December 2020

Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery.

1 reference

12 December 2020

Isolation and functional analysis of alternative promoters in the human aquaporin-4 water channel gene

1 reference

12 December 2020

Effects of cyclo-oxygenase inhibition on vasodilatory response to acetylcholine in patients with type 1 diabetes and nondiabetic subjects.

1 reference

12 December 2020

Role of prostacyclin in the cardiovascular response to thromboxane A2

1 reference

12 December 2020

Cyclooxygenase-1 and cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs: investigation using human peripheral monocytes

1 reference

12 December 2020

Association of nonsteroidal anti-inflammatory drugs with first occurrence of heart failure and with relapsing heart failure: the Rotterdam Study

1 reference

12 December 2020

Indobufen is a potent inhibitor of whole blood aggregation in patients with a high atherosclerotic risk

1 reference

12 December 2020

Fluid shear stress-induced cyclooxygenase-2 expression is mediated by C/EBP beta, cAMP-response element-binding protein, and AP-1 in osteoblastic MC3T3-E1 cells

1 reference

12 December 2020

Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis

1 reference

12 December 2020

The cyclooxygenase-2-specific inhibitor parecoxib sodium is as effective as 12 mg of morphine administered intramuscularly for treating pain after gynecologic laparotomy surgery

1 reference

12 December 2020

Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial

1 reference

12 December 2020

Effects of Cyclooxygenases Inhibitors on Vasoactive Prostanoids and Thrombin Generation at the Site of Microvascular Injury in Healthy Men

1 reference

12 December 2020

Ibuprofen interferes with the efficacy of antihypertensive drugs. A randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen

1 reference

12 December 2020

Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy M

1 reference

12 December 2020

COX-2-specific inhibitors and the kidney: effect on hypertension and oedema

1 reference

12 December 2020

Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure

1 reference

12 December 2020

Prostaglandin H synthase and vascular function

1 reference

12 December 2020

N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arte

1 reference

12 December 2020

Indobufen compared with aspirin and dipyridamole on graft patency after coronary artery bypass surgery: results of a combined analysis

1 reference

12 December 2020

Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study

1 reference

12 December 2020

Treatment of congenital nephrogenic diabetes insipidus by hydrochlorothiazide and cyclooxygenase-2 inhibitor

1 reference

12 December 2020

Spontaneous reports of hypertension leading to hospitalisation in association with rofecoxib, celecoxib, nabumetone and oxaprozin

1 reference

12 December 2020

Evaluation of flurbiprofen for prevention of reinfarction and reocclusion after successful thrombolysis or angioplasty in acute myocardial infarction. The Flurbiprofen French Trial

1 reference

12 December 2020

Antithrombotic drugs in the primary medical management of intermittent claudication: a meta-analysis

1 reference

12 December 2020

Renal failure associated with the use of celecoxib and rofecoxib

1 reference

12 December 2020

Opposite effects of rofecoxib on nuclear factor-kappaB and activating protein-1 activation

1 reference

12 December 2020

Relative thromboembolic risks associated with COX-2 inhibitors

1 reference

12 December 2020

Aspirin-triggered, cyclooxygenase-2-dependent lipoxin synthesis modulates vascular tone

1 reference

12 December 2020

Acute myocardial hypoxia increases BNP gene expression

1 reference

12 December 2020

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

1 reference

12 December 2020

Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem.

1 reference

12 December 2020

The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus

1 reference

12 December 2020

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

1 reference

12 December 2020

Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis

1 reference

12 December 2020

Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly

1 reference

12 December 2020

Efficacy of rofecoxib, celecoxib, and acetaminophen in patients with osteoarthritis of the knee. A combined analysis of the VACT studies

1 reference

12 December 2020

10.1007/S00210-006-0044-7

Identifiers

DOI

1 reference

14 August 2017

1 reference

PubMed ID

16586083